|
Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions
|
Jul 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
|
Oct 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience
|
Nov 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?
|
Nov 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience
|
Sep 2020
|
Leukemia & Lymphoma
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria
|
Dec 2019
|
Leukemia & Lymphoma
|
aplastic anemia
|
|
What causes aplastic anaemia?
|
Apr 2023
|
Leukemia
|
aplastic anemia
|
|
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents
|
Jan 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
|
Jun 2016
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Distinct iron architecture in SF3B1 mutant myelodysplastic syndromes patients is linked to an SLC25A37 splice variant with a retained intron
|
May 2014
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
